糖尿病周围神经病变疼痛的药物治疗与生活质量:系统综述
该系统综述评估了糖尿病周围神经病变(DPN)药物治疗对疼痛和生活质量的影响。研究更新了57项合格研究并新增24项已发表和25项未发表研究,发现度洛西汀和文拉法辛(中等强度证据)、普瑞巴林和奥卡西平(低强度证据)、三环类抗抑郁药(低强度证据)、非典型阿片类药物(低强度证据)及肉毒毒素(低强度证据)在减轻神经病理性疼痛方面优于安慰剂。由于报告不完整,无法就生活质量得出结论;所有研究均为短期(不足6个月),有效药物因不良反应退出率均超过9%。
要点
- 度洛西汀和文拉法辛(中等强度证据)可有效减轻DPN疼痛。
- 普瑞巴林、奥卡西平、三环类抗抑郁药、非典型阿片类和肉毒毒素(低强度证据)也优于安慰剂。
- 生活质量报告不足,无法得出结论;研究均短期,药物退出率超9%。
核心结论
- 度洛西汀和文拉法辛、普瑞巴林和奥卡西平、三环类抗抑郁药、非典型阿片类药物及肉毒毒素在减轻DPN疼痛方面优于安慰剂。
- 由于报告不完整,无法就生活质量得出结论;所有研究均为短期(不足6个月),有效药物因不良反应退出率均超过9%。
研究设计与样本
- 更新了近期完成的57项合格研究的系统综述,新增24项已发表研究和25项未发表研究。
- 两名评价员独立评估研究资格、连续摘录数据、独立评估偏倚风险并分级证据强度(SOE)。
主要发现
- 度洛西汀和文拉法辛(中等强度证据)、普瑞巴林和奥卡西平(低强度证据)、三环类抗抑郁药(低强度证据)、非典型阿片类药物(低强度证据)及肉毒毒素(低强度证据)在减轻神经病理性疼痛方面优于安慰剂。
- 由于报告不完整,无法就生活质量得出结论。
- 所有研究均为短期(不足6个月),所有有效药物因不良反应退出率均超过9%。
关键数值与推荐
- 度洛西汀和文拉法辛:中等强度证据支持减轻DPN疼痛。
- 普瑞巴林和奥卡西平:低强度证据支持减轻DPN疼痛。
- 三环类抗抑郁药:低强度证据支持减轻DPN疼痛。
- 非典型阿片类药物:低强度证据支持减轻DPN疼痛。
- 肉毒毒素:低强度证据支持减轻DPN疼痛。
临床怎么用
- 对于DPN疼痛,可考虑使用度洛西汀、文拉法辛、普瑞巴林、奥卡西平、三环类抗抑郁药、非典型阿片类药物或肉毒毒素,但需注意证据强度不同。
- 使用这些药物时需关注不良反应导致的退出率较高(超过9%),尤其是阿片类药物具有显著风险。
- 由于生活质量数据不足且研究均为短期,临床决策应结合患者具体情况并关注长期疗效和生活质量。
局限性
- 生活质量报告不完整,无法得出结论。
- 所有研究均为短期(不足6个月)。
- 有效药物因不良反应退出率均超过9%。
- 阿片类药物具有显著风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To systematically assess the effect of pharmacologic treatments of diabetic peripheral neuropathy (DPN) on pain and quality of life. METHODS: We searched PubMed and Cochrane Database of Systematic Reviews for systematic reviews from 2011 to October 12, 2015, and PubMed, Embase, and the Cochrane Central Register of Controlled Trials for primary studies from January 1, 2013, to May 24, 2016. We searched Clinicaltrials.gov on March 9, 2016. Two reviewers independently evaluated studies for eligibility, serially abstracted data, and independently evaluated risk of bias and graded strength of evidence (SOE). RESULTS: We updated a recently completed systematic review of 57 eligible studies with 24 additional published studies and 25 unpublished studies. For reducing neuropathy-related pain, the serotonin-norepinephrine reuptake inhibitors duloxetine and venlafaxine (moderate SOE), the anticonvulsants pregabalin and oxcarbazepine (low SOE), the drug classes tricyclic antidepressants (low SOE) and atypical opioids (low SOE), and botulinum toxin (low SOE) were more effective than placebo. We could not draw conclusions about quality of life due to incomplete reporting. All studies were short-term (less than 6 months), and all effective drugs had more than 9% dropouts from adverse effects. CONCLUSIONS: For reducing pain, duloxetine and venlafaxine, pregabalin and oxcarbazepine, tricyclic antidepressants, atypical opioids, and botulinum toxin were more effective than placebo. However, quality of life was poorly reported, studies were short-term, drugs had substantial dropout rates, and opioids have significant risks. Future studies should evaluate longer-term outcomes, use methods and measures recommended by pain organizations, and assess patients' quality of life.
引用
- Waldfogel JM, Nesbit SA, Dy SM, et al. Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life: A systematic review. Neurology. 2017. PMID: 28341643. doi:10.1212/WNL.0000000000003882
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。